Bookmark
Forward
QuickView for Mivacurium (compound)
PubChem
| Name: | mivacurium |
|---|---|
| PubChem Compound ID: | 104803 |
| Molecular formula: | C58H80N2O14+2 |
| Molecular weight: | 1029.26 g/mol |
| Synonyms: |
6918-08-7
|
DrugBank
Identification
| Name: | mivacurium |
|---|---|
| Name (isomeric): | DB01226 |
| Drug Type: | small molecule |
| Brand: | Mivacron |
| Category: | Neuromuscular Nondepolarizing Agents |
| CAS number: | 106791-40-6 |
Pharmacology
| Indication: | For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. |
|---|---|
| Pharmacology: |
Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by miv...
show more » |
| Mechanism of Action: | Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. |
| Protein binding: | The protein binding of mivacurium has not been determined due to its rapid hydrolysis by plasma cholinesterase. |
| Biotransformation: | Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality. |
| Half Life: | The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value. |
| Toxicity: | Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
